GlassScriptPhysician profile
Tamorie L Smith
NPI 1215140496
$3,764.73
in general payments reported to CMS, 2019-2025
28 companies · $884 in 2025
The $884 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2020: $99.26 · 2021: $352 · 2022: $659 · 2023: $543 · 2024: $895 · 2025: $884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,138 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,138.37 |
| Education | $183.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $615.99 | 2020-2025 | Farxiga, Lokelma |
| Mallinckrodt Hospital Products INC. | $451.40 | 2021-2025 | Acthar |
| Akebia Therapeutics INC | $323.21 | 2019-2025 | Vafseo, Auryxia |
| Otsuka America Pharmaceutical, INC. | $276.54 | 2019-2025 | Jynarque |
| Baxter Healthcare | $251.76 | 2019-2024 | Renal - Pd, Renal - Acute |
| Opko Pharmaceuticals, LLC | $189.12 | 2019-2025 | Rayaldee |
| Novo Nordisk INC | $175.12 | 2024-2025 | Rybelsus, Ozempic |
| Vifor Pharma, INC. | $173.22 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $172.07 | 2022-2025 | |
| Travere Therapeutics, INC. | $165.54 | 2020-2025 | Filspari |
| Amgen INC. | $155.66 | 2021-2025 | Krystexxa, Aranesp, Parsabiv |
| Glaxosmithkline, LLC. | $146.16 | 2021-2023 | Benlysta |
| Novartis Pharmaceuticals Corporation | $108.83 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $101.76 | 2022-2025 | Tarpeyo |
| Ardelyx, INC. | $93.67 | 2023-2025 | Ibsrela |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $87.98 | 2022-2023 | Ultomiris, Soliris |
| Cormedix INC. | $63.60 | 2024 | Defencath |
| Fresenius USA Marketing, INC. | $54.85 | 2019-2024 | Velphoro |
| Alnylam Pharmaceuticals INC. | $52.00 | 2021-2024 | Oxlumo |
| Daiichi Sankyo INC. | $32.63 | 2021-2024 | Injectafer |
| Mallinckrodt Enterprises LLC | $23.12 | 2019 | |
| Apellis Pharmaceuticals, INC. | $19.55 | 2025 | Empaveli |
| Horizon Therapeutics Plc | $15.52 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.43 | 2025 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamorie Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.